Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

Jennifer Gill; Adam J. Obley; Vinay Prasad

doi:10.1001/jama.2018.5330

Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

Jennifer Gill, Adam J. Obley, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

44 Scopus citations

Original language	English (US)
Pages (from-to)	2377-2378
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	319
Issue number	23
DOIs	https://doi.org/10.1001/jama.2018.5330
State	Published - Jun 19 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2018.5330

Cite this

@article{6a32094549f449b2bd027fa7f63064c0,

title = "Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing",

author = "Jennifer Gill and Obley, {Adam J.} and Vinay Prasad",

year = "2018",

month = jun,

day = "19",

doi = "10.1001/jama.2018.5330",

language = "English (US)",

volume = "319",

pages = "2377--2378",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "23",

}

TY - JOUR

T1 - Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

AU - Gill, Jennifer

AU - Obley, Adam J.

AU - Prasad, Vinay

PY - 2018/6/19

Y1 - 2018/6/19

UR - http://www.scopus.com/inward/record.url?scp=85049262875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049262875&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.5330

DO - 10.1001/jama.2018.5330

M3 - Review article

C2 - 29800087

AN - SCOPUS:85049262875

SN - 0098-7484

VL - 319

SP - 2377

EP - 2378

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 23

ER -

Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this